Summary The activty and toxicity of single-agent standard-dose doxorubicin were compared with that of two schedules of high-dose epirubicin. A total of 334 chemonaive patients with histologically confirmed advanced soft-tissue sarcomas received (A) doxorubicin 75 mg m-2 on dcay 1 (112 patients), (B) epirubicin 150 mg m-2 on day 1 (111 patients) or (C) epirubicin 50 mg m-2 day-1 on days 1, 2 and 3 (111 patients); all given as bolus injection at 3-week intervals. A median of four treatment cycles was given. Median age was 52 years (19-70 years) and performance score 1 (0-2). Of 314 evaluable patients, 45 (14%) had an objective tumour response (eight complete response, 35 partial response). There were no differences among the three groups. Median time to progression for groups A, B and C was 16, 14 and 12 weeks, and median survival 45, 47 and 45 weeks respectively. Neither progression-free (P = 0.93) nor overall survival (P = 0.89) differed among the three groups. After the first cycle of therapy, two patients died of infection and one owing to cardiovascular disease, all on epirubicin. Both dose schedules of epirubicin were more myelotoxic than doxorubicin. Cardiotoxicity (> grade 3) occurred in 1%, 0% and 2% respectively. Regardless of the schedule, high-dose epirubicin is not a preferred alternative to standard-dose doxorubicin in the treatment of patients with advanced softtissue sarcomas.
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In the primary treatment of adult soft-tissue sarcomas. local treatments xxith surgen and adjuxant radiotherapy are essential for achievinc long-term survixal (Robinson. 1994 : Suit. 1995 . Hoxexver. despite optimal local treatment of the primarv tumour. disseminated disease will dexelop in many patients. Consequently. chemotherapy has been extensively studied in soft-tissue sarcomas : Verxxeij et al. 1995 . Unfortunately. their responsix eness to chemotherapy has been disappointinglx low.
Although doxorubicin was one of the first agents reported to haxe actixitv (Gottlieb et al. 1975) . it still appears to be one of the most active drugs in the treatment of soft-tissue sarcomas . Txxo other drugs with demonstrated first-line activitx in soft-tissue sarcomas are ifosfamide and dacarbazine (Blackledge et al. 1990) . Although their study desigyn has been criticized. O'Brvan et al (1973) have indicated a strong dose-response relationship for doxorubicin. To obtain optimal response rates. a dose of at least 70 mg m-' evenr 3 wxeeks appears to be necessary.
Oxer the last 20 y-ears. the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) has investigated different drug combinations as first-line chemotherapy in several randomized trials . In those studies. no regimen has demonstrated any advantage in terms of response rate as well as progression-free and overall sun, ixal compared x-ith single-agent doxorubicin 75 mg m-' given even 3 weeks (Verxeij et al. 1995 : Santoro et al. 1995 (Bramxell et al. 1983 : Bull et al. 1985 . In a randomized study comparing doxorubicin and epirubicin both at a dose of 75 mg m-'2 no difference in survival and duration of response was found. and the response rate was only slightly in favour of doxorubicin (Mouridsen et al, 1987) . However, this was achieved at the expense of toxicity, which was significantly more pronounced for doxorubicin. These data indicate that epirubicin may be less toxic than doxorubicin when administered in equipotent doses. Consequently, increasing the epirubicin dose could lead to a greater antineoplastic effect with acceptable toxicity. It is now known that much higher doses of epirubicin can be applied (Chevalier et al, 1990; Jelic et al. 1990: Plosker and Faulds, 1993) . Moreover, at the time of starting the present study, it was believed that alterations in the pharmacokinetic principles could result in enhanced treatment efficacy without or with only minor alterations in toxicity. Cardiac toxicity may be related to the peak concentration of the drug, and lower toxicity could. therefore, be expected with fractionated schedules compared with high-dose epirubicin given as a bolus injection. In view of this, the EORTC STBSG initiated a randomized phase 3 study comparing standard-dose doxorubicin 75 mg m-2 with two schedules of high-dose epirubicin. either 150 mg m-2 as a single bolus or 50 mg m-2 day-' bolus injection for 3 consecutive days. The present report gives the final results of this study. 
MATERIALS AND METHODS

Therapeutic regimens
Patients were initially randomized to receive (a) an i.v. bolus injection of doxorubicin 75 mg m-2 every 3 weeks, or (b) epirubicin at a dose of either 160 mg m-2 as a single i.v. bolus injection or (c) three i.v. bolus injections of 60 mg m-2 on days 1. 2 and 3. both repeated every 3 weeks. The last two dose schedules had been reported to be feasible by others (Chevalier et al. 1988; Jelic et al, 1990 ). Because of severe and lethal neutropenia in the first patients. the epirubicin doses were reduced to 150 mg m-2 and 3 x 50 mg m-2 day-'. respectively. and administered as a 30-min i.v.
infusion. Only 20 patients (28 cycles) received the higher doses.
Dose modificatios
The evaluation of toxicity was carried out according to the recommendation made by WHO for grading of acute and subacute toxic effects. In patients with haematological toxicity WHO grade 1 and 2 at the start of the next cycle. the treatment was postponed for 1 week. If the start of a cycle was postponed by more than 3 weeks. the patient went off study. In case of nadir WBC < 0.5 x 109 1-1 (or < 1.0 x 109 1-1 + infection) and/or platelets < 50 x 109 1-'. the drug dose was reduced by 20%. In case of a decrease in cardiac ejection fraction to < 50% at rest or < 60% at maximal exercise. it was at the discretion of the investigator to stop treatment. If grade 3 or 4 mucositis occurred. the dose was reduced by 20%.
Treatment duration
At least two cycles were given. except in the case of rapid disease progression. The maximal accepted cumulative dose was 550 mg m-2 for doxorubicin and 1000 mg m-for epirubicin. When six cycles of chemotherapy had been administered and the cumulative dose achieved. two additional cycles could be given at the decision of the clinician. Patients achieving a complete response were recommended to continue treatment for at least two more cycles until the maximum cumulative dose was reached. Otherwise. patients continued treamnt until disease progression. maximum cumulative dose, unacceptable toxicities or patient refusal.
Pretreatment and follow-up evaluations
Evaluation before treatment included history and clinical examination. performance status, tumour measurements (computerized tomography or ultrasound scans). haematology (haemoglobin. WBC. platelet counts). blood chemistry (urea. electrolytes. creatinine, calcium. bilirubin. alkaline phosphatase. aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT), lactate dehydrogenase, plain chest radiograph. electrocardiogram (ECG) . bone scan and/or radiograph (optional). and cardiac (radio nuclide) ejection fraction. Blood counts were performed weekly during teatmnt for the initial two treatment cycles. At follow-up. clinical examination as well as blood counts and chemistries were performed before every cycle. Chest radiograph, tumour measurements, ECG and cardiac ejection fraction (optional) were carried out every second course. In patients receiving more than six cycles. the cardiac ejection fraction was measured before each treatment.
Definition of response
Patients were considered assessable for response if they had received at least two cycles of chemotherapy. Response was defined according to the WHO criteria. Progression-free and overall survival were computed from the date of randomization. The period of overall response was computed from the first day of treatment to the date of first observation of progressive disease.
British Journal of Cancer (1998) 78(12) 15 (14) 17 (16) 15 (14) Hisologcl grade 1 (%) 22 (21) 18 (17) 25 (24) The period of complete response (CR) lasted from the date CR was first recorded to the date of progression. Patients progressing after one cycle were classified as treatment failures. Patients taken off study after one cycle because of toxicity were considered inevaluable for response, but remained evaluable for toxicity.
Stas_l conskeraoo
The aim of the trial was to evaluate whether the 30% response rate obtained in the previous trial of our group with standard-dose doxorubicin could be increased to 45% with one of two high-dose epirubicin regimens. The tral was conducted in two phases. In the first part, a total of 30 patients was randomized in each treatment arm, and the data analysed as a randomized phase II trial. As the toxicity and the number of responses in the epirubicin groups were acceptable after the dose reduction after the first 20 patients were entered, the trial was continued as planned as a phase EII study. For this purpose, 100 additional patients in each treatment group had to be randomized. This would enable the detection of a 15%
increase in a response rate (a = 0.05, 0 = 0.2, one tailed).
Because of decrease in the recruitment rate, an interim analysis was perforned and discussed with an Independent Data Monitoring Committee. The Committee decided to stop recruitment and publish the data because of the high toxicity profile of the Epirubicin groups and their lack of improvement in response rate, making also an improvement in time to progression or overall survival unlikely. At that stage, the sample size was sufficient to detect the 15% increase in response rate between the two epirubicin groups analysed together and the doxorubicin group.
The 20 patients who received the higher doses of epirubicin (160 mg m-2 and 60 mg m-2 x 3) are included in all analyses. Thus, the paper is based on all 334 randomized patients including the 90 patients of the phase H study, of which 314 patients were eligible.
Exact 95% confidence intervals for proportions were calculated for response rates. Duration of response, progression-free and overall survival were estimated by use of the Kaplan-Meier (Vantongelen et al, 1989 ).
RESULTS
Paten chaacte sUcs
A total of 334 patients from 34 centres were included. Fifteen patients were considered as ineligible for the trial for the following reasons: ineligible type of sarcoma (n = 6), histology other than sarcomas (n = 2), no target lesion (n = 1), concurrent disease (n = 2), age > 70 years (n = 1), performance status > 2 (n = 1), prior breast cancer (n = 1) and prior chemotherapy (n = 1). An additional five patients were lost during follow-up. In total, 20 patients were excluded from the analysis, which consequently was based on 314 patients (Table 1) .
Covariates were evenly distributed among the three treatment groups with regard to age, sex, performance status, histological grades, sites of involvement, and prior treatment (Table 1 ). Only 20% of the patients were younger than 40 years, and 25% were older than 60 years. Bone metastases were reported for 7% of the patients, but this was not systematically investigated because bone metastases were not permitted as measurable disease.
A central histopathology review was performed in 265 (83%) of the patients. In the three treatment groups (doxorubicin, 1-day epirubicin and 3-day epirubicin), leiomyosarcomas contributed 41%, 41% and 38%, respectively, whereas liposarcomas contributed 13%, 12% and 8% and malignant fibrous histiocytoma 10%, 11% and 10% respectively. The other histopathological types were equally distributed among the other patients (data not shown). Prior radiotherapy was given to 69 (22%) of the patients.
Trea_tmet compliance
Treatmnt compliance did not differ among the three treatment groups. The patients received a median of four cycles, ranging from 0 to 11 cycles. Only six patients received more than eight cycles. In all but one, the dose had been reduced at an earlier stage, and, therefore, they did not receive more than 1200 mg m-2 epiubin One patent received nine cycles at full dose, and a total dose of 1316 mg m-2 Epirubicin vs doxorubicin in soft tissue sarcomas 1637 and P = 0.007 (3-day schedule]. whereas the increase in mucositis was not statistically significant (P = 0.53 and P = 0.09). In addition.
the followinc,grade 3 side-effects were observed w ith the 1-day and 29% in 1983 29% in (Bramwell et al, 1983 . 25% im 1987 (Mouridsen et al. 1987) . 22% in 1995 (Santoro et al, 1996) and 14% in the present study. We found a relative dose intensity of doxorubicin of 97% (Table 2) . Thus, inadequate dose intensity was not the reason for the poor response rate. In rare diseases such as soft-tissue sarcomas, patient selection may give variations in the reported response rates. Thus, to understand the low response rate, the known prognostic factors for response were compared between the present study and two other large trials of our group (Pinedo et al. 1984; Santoro et al, 1995) . Neither variation in the proportion of liver metastases nor the median age fully explained the observed difference in response rates. In the present study, the number of leiomyosarcomas was slightly higher than that of previous studies, and we are presently analysing to what extent this change in histological frequencies may explain the low response rate. Finally, a more rigid assessment of response may also contribute to the falling response rates -an explanation that is also currently being investigated.
Four randomized studies have been performed by ECOG and EORTC comparing single-agent doxorubicin with different combination chemotherapy regimnens (Edmonson et al, 1993; Verweij et al, 1995) . Although the response rates were slightly higher for some of the combination chemotherapy regimens, they were not associated with an improved survival. Tberefore, it has been concluded that standard-dose doxorubicin is as effective as combination chemotherapy (Santoro et al, 1995; Verweij et al, 1995) , and the disappointingly low response rates obtained in the present study once again stresses the primary resistance of softtissue sarcomas to chemotherapy and the need for new active drugs. Unfortunately, there is a generl lack of information on the mechanisms of drug resistance in this disease.
In conclusion, regardless of the schedule, high-dose epirubicin did not increase progression-free survival, overall survival or response rate compared with standard-dose doxorubicin. We recommend that on the basis of equivalent efficacy, but reduced toxicity and expense, standard-dose doxorubicin is the preferred anthracycine in advanced soft-tissue sarcoma, as compared with high-dose epirubicin.
